Identification of biomarkers to improve the diagnosis and treatment of Multiple Sclerosis by Perna, Laura
U n iv er s i ty o f  H u d d e r s f i e l d  R e p o s i t ory
Pe r n a,  Lau r a
Ide n tifica tion  of bio m a rk e r s  to  imp rove  t h e  di a g nosis  a n d  t r e a t m e n t  of 
M ul tiple  Scle ro sis
Ori g i n a l  Cita t i o n
Pe r n a,  Lau r a  (202 0) Ide n tifica tion  of bio m a rk e r s  to  imp rove  t h e  di a g nosis  a n d  
t r e a t m e n t  of M ul tiple  Scle rosis.  M a s t e r s  t h e sis, U nive r si ty of H u d d e r sfield. 
This  ve r sion  is available  a t  h t t p:// ep rin t s .h u d. ac.uk/id/ ep rin t/354 9 5/
The  U nive r si ty Re posi to ry is a  digi t al  collec tion  of t h e  r e s e a r c h  ou t p u t  of t h e
U nive r si ty, available  on  Op e n  Access .  Copyrig h t  a n d  Mo r al  Righ t s  for  t h e  
it e m s
on  t hi s  si t e  a r e  r e t ain e d  by t h e  individu al a u t ho r  a n d/o r  o t h e r  copyrigh t  
ow n e r s .
U s e r s  m ay  a cc e s s  full it e m s  fr e e  of c h a r g e;  copie s  of full t ex t  it e m s  g e n e r ally
c a n  b e  r e p ro d uc e d,  dis pl aye d  o r  p e rfo r m e d  a n d  given  to  t hi rd  p a r ti e s  in a ny
for m a t  o r  m e diu m  for  p e r son al  r e s e a r c h  o r  s t u dy, e d u c a tion al  o r  no t-for-p rofi t
p u r pos es  wi tho u t  p rio r  p e r mission  o r  c h a r g e ,  p rovide d:
• The  a u t ho r s,  ti tl e  a n d  full bibliog r a p hic  d e t ails  is c r e di t e d  in a ny copy;
• A hyp e rlink  a n d/o r  URL is includ e d  for  t h e  o riginal m e t a d a t a  p a g e;  a n d
• The  con t e n t  is no t  c h a n g e d  in a ny w ay.
For  m o r e  info r m a tion,  including  ou r  policy a n d  s u b mission  p roc e d u r e ,  ple a s e
con t ac t  t h e  Re posi to ry Tea m  a t :  E. m ailbox@h u d.ac.uk.





Identification of biomarkers to improve the 












A thesis submitted to the University of Huddersfield in partial 
fulfilment of the requirements for the degree of Master of 










Index                                                                                                                                
Abstract .................................................................................................................................................. 5 
Chapter 1: Introduction ........................................................................................................................ 6 
1.1 Pathology of MS ....................................................................................................................... 6 
1.2 Clinical forms of MS .................................................................................................................. 9 
1.3 Aetiology of MS ...................................................................................................................... 12 
1.4 Diagnosis of MS ..................................................................................................................... 18 
1.5 Classification of MS biomarkers ............................................................................................. 19 
1.6 Techniques for investigation of biomarkers ............................................................................ 23 
1.7 XBP1 gene ............................................................................................................................. 24 
1.8 Volatile organic compounds ................................................................................................... 26 
1.9 Purpose of the thesis .............................................................................................................. 29 
Chapter 2: Materials and Methods .................................................................................................... 31 
2.1 Human brain tissue ................................................................................................................. 31 
2.2 Immunohistochemistry PLP, XBP1s/u staining  ...................................................................... 33 
2.3 Immunohistochemistry XBP1 s/u ............................................................................................ 34 
        2.4 Microscopy .............................................................................................................................. 34 
2.5 IHC analysis and statistics ...................................................................................................... 35 
        2.6 Breath study population .......................................................................................................... 36 
2.7 Breath biopsy test ................................................................................................................... 37 
2.8 VOCs analysis and statistics ................................................................................................... 39 
Chapter 3: Results .............................................................................................................................. 40 
         3.1 XBP1 S and XBP1 U in MS forms ......................................................................................... 40 
         3.2 XBP1 S/U ratio ....................................................................................................................... 44 
         3.3 XBP1 S and XBP1 U in lesions .............................................................................................. 46 
         3.4 VOCs in MS and healthy controls participants ...................................................................... 50 
Chapter 4: Discussion ........................................................................................................................ 51 
         4.1 Lead biomarkers in MS field  ................................................................................................. 51 
         4.2 XBP1 expression in MS patients ............................................................................................ 55 
         4.3 VOCs and their potential ........................................................................................................ 55 
         4.4 IHC as biomarker detection technique ................................................................................... 56 
         4.5 IHC limitations ........................................................................................................................ 57 
         4.6 Future experiments ................................................................................................................ 57 
         4.7 Conclusions ............................................................................................................................ 57 





List of Tables  
Table 1 Primary antibodies used and 
respective dilution. 
 













List of Figures List of Figures 
Figure 1.1: Representation of the white 
matter 
Figure 1.14: Exchange from blood to 
airflows 
Figure 1.2: Representation of the grey 
matter 
Figure 1.15: Aims and objectives 
Figure 1.3: Clinical course of Relapsing 
Remitting Multiple Sclerosis 
Figure 2.1: Immunohistochemistry cases 
details 
Figure 1.4:  Clinical course of Primary 
Progressive Multiple Sclerosis 
Figure 2.2: Breath biopsy cases details 
Figure 1.5:  Clinical course of Secondary 
Progressive Multiple Sclerosis 
Figure 2.3: ReCIVA Breath Sampler 
machine 
Figure 1.6: Scheme of the inside-
out/outside-in model 
Figure 2.4: ReCIVA Breath software 
Figure 1.7: Pathogenic mechanism that 
intervene in multiple sclerosis 
Figure 3.1: XBP1 images at confocal 
microscopy 
Figure 1.8: Electron microscopy image of 
an acute demyelinating lesion of multiple 
sclerosis 
Figure 3.2: IHC technical standardization 
Figure 1.9: Autopsy material from patients 
in early active stages of multiple sclerosis 
Figure 3.3:  XBP1 expression in Multiple 
sclerosis cases and controls 
Figure 1.10: Cortical lesions contain less 
inflammatory cells than white matter lesions 
Figure 3.4:  XBP1 s/u ratio in all Multiple 
sclerosis forms and controls. 
Figure 1.11: Normal appearing white matter 
of a patient showing myelin and axonal loss 
but reduced immune infiltration 
Figure 3.5:  XBP1 expression in Multiple 
sclerosis lesions. 
Figure 1.12: Diagnostic biomarker currently 
used 
Figure 3.6:  XBP1 s/u ratio in lesions. 





List of Acronyms List of Acronyms 
AD = Alzheimer’s disease HER2 = Human epidermal growth factor 
receptor-2 
ALS = Amyotrophic lateral sclerosis IBD = Inflammatory bowel disease 
ALK = Anaplastic lymphoma kinase IFN = Interferon 
APC = Antigen presenting cell IHC = Immunohistochemistry 
AQP4 = Acquaporin-4 IRE1α = Inositol requiring enzyme one 
alpha 
ASD = Autism spectrum disorder JCV = John Cunningham virus 
ASCO = American society of clinical 
oncology 
LFA-1 = Lymphocyte function-associated 
antigen 1 
ATF6 = Activating transcription factor 6 MAG = Myelin associated glycoprotein 
BB = Breath biopsy MET = Hepatocyte growth factor receptor 
BD = Bipolar disorder MHC = Major histocompatibility complex 
BG = Basal ganglia miRNA = Micro RNA 
BMI = Body mass index MRI = Magnetic resonance imaging 
CAP = College of American pathologists MS = Multiple Sclerosis 
CIS = Clinical isolated syndrome NAGM = Normal appearing grey matter 
CNS = Central nervous system NAWM = Normal appearing white matter 
CTRL = Controls NGS = Next-generation sequencing 
DAB = Diaminobenzidine tetrachloride NIST = National Institute of Standards and 
Technology 
DAPI = 4'6-Diamidino-2-Phenylindole PBMC = Peripheral blood mononuclear cell 
DAWM = Diffusely abnormal WM PBS = Phospho-buffered saline 
DBS = Dynamic background subtraction PCR = Polymerase chain reaction 
EBNA = Epstein Barr virus nuclear antigen PERK = Pancreatic endoplasmic reticulum 
kinase 
EDSS = Expanded Disability Status Scale PD-L1 = Programmed death ligand-1 
EGFR = Epidermal growth factor receptor PLP = Proteolipid protein, myelin 
ELISA = Enzyme-linked immunosorbent 
assay 
PML = Progressive multifocal 
leukoencephalopathy 
ER = Endoplasmic reticulum PP = Primary progressive 
ERAD = ER associated protein degradation RR = Relapsing remitting 
FC = Frontal cortex SP = Secondary progressive 
FFPE = Formalin-fixed paraffin-embedded TL = Temporal lobe 
FGFR = Fibroblast growth factor receptor TOF-MS = Time-of-flight Mass 
spectrometry 
FISH = In situ hybridization UPR = Unfolded protein response 
GFAP = Glial fibrillary acidic protein UV = Ultraviolet  
GM = Grey matter VOCs = Volatile organic compounds 
GC-MS = Gas chromatography mass 
spectrometry 
VLA-4 = Very late activation antigen 4 










Worldwide, 2.5 million of people are affected by multiple sclerosis, most commonly between 
20 and 40 years old, with a prevalence among females. The lack of consensus over the causes 
of this disease is depicted by the presence in the literature of two antithetic visions about the 
multiple sclerosis etiopathogenesis. This has dramatic consequences on the clinical approach 
to the disease, which presently can be effective for a restricted percentage of patients, and on 
the market, currently ruled by immunomodulator drugs. This variability is one of the key points 
in the research of biomarkers for multiple sclerosis, and in this thesis, conducted at University 
of Huddersfield and at the Centre for Biomarker Research, two emerging targets are 
evaluated. The first one, the XBP1 gene, involved in endoplasmic reticulum stress response, 
codes two different isoforms that we evaluated through immunohistochemistry in post-mortem 
human brains of multiple sclerosis patients and healthy controls, in three areas: the frontal 
cortex, the basal ganglia and the temporal lobe. We found that the expression and the ratio of 
these isoforms are dysregulated between multiple sclerosis patients and controls. The second 
biomarker candidate investigated, instead, are the volatile organic compounds, collected via 
breath samples of multiple sclerosis participants and healthy controls. Unfortunately, due to 
the novel Coronavirus pandemic, the results of this study cannot be analysed further, but the 
methodology used in order to perform the breath tests was positively evaluated as non-



















1.1 PATHOLOGY OF MS 
Multiple Sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central 
nervous system (CNS), which most commonly affects young adults between 20 and 40 years 
old (Calabrese et al., 2015). The main target of this disease is the myelin sheath, the 
membrane that covers neurons and which biological functions are electrical insulation, 
allowing a faster signal transduction, protection, compaction, maintenance and development 
of the CNS and the peripheral nervous system (Greenfield et al., 2006). The myelination 
process happens with the involvement of myelin-specific proteins: the myelinating glial cell 
establishes its contact with axons by covering it with its glial plasma membrane for a number 
of times (Han, Myllykoski, Ruskamo, Wang, & Kursula, 2013). When the myelin sheath is 
damaged or removed, the conduction of impulses along nerve fibres slows down or fails, 
leading to an impairment of brain functionality; in the case of MS this is clinically related with 
motor and cognitive impairments (Pronk et al., 2008). 
The distinctive features of MS are the lesions where the focal demyelination occurs, 
accompanied by infiltrations of the immune system and glial activation (Awal et al., 2018). 
These lesions are disseminated in space and time at the CNS level. In particular, the most 
studied are those of the white matter (WM) because they are easier to examine and visualize 





Figure 1.1 Representation of the white matter.  
(A) Image of WM in the brain (ADAM Health, 2020). (B) WM portion visible by PLP (proteolipid 
protein,myelin) staining and WM lesion highlighted by the lack of stained PLP in the area delineated by 
the yellow dotted lines Image scale bars: 50 μm (Dunham et al., 2017). 
 
The WM is a portion of the brain organized in nerve fibres and myelin (Fields, 2008). The 
normal appearing white matter (NAWM), instead, is defined as a portion of the brain in which 
the myelin appears normal and no inflammatory factors are present (Bramwell & Jones, 1941). 
The grey matter (GM) contains the same connections of the WM but lesser in number, it is 
mostly characterized by cell bodies, dendrites and axon terminals of neurons and even if 
lesions are localised there, they are hard to visualize through magnetic resonance imaging, 
so most of the studies have been performed through neuropathological techniques on autoptic 






Figure 1.2 Representation of the grey matter.  
(A) Image of GM in the brain (ADAM Health Solutions). (B) GM portion visible by PLP staining Image 
scale bars: 100 μm (Dunham et al., 2017). 
 
The lesions show differences between grey and white matter not only according to the 
morphology and the position, but also to the degree of lymphocyte infiltration, complement 
deposition, and blood–brain barrier disruption, which are not present in GM lesions, showing 
inflammatory features just in the WM (Geurts, Stys, Minagar, Amor, & Zivadinov, 2009). 
Despite being known for more than a century, at the moment there is no consensus over the 
causes of this debilitating disorder, and consequently, the pharmacological strategies are 
simply aiming to reduce the immunological and inflammatory symptoms of the patients 














1.2 CLINICAL FORMS OF MS 
There are several classifying criteria developed in order to diagnose the different types of MS 
forms. The first ones appeared are the Schumacher Criteria (Schumacher et al., 1965) that 
were based on clinical findings. Then, in 1983, thanks to the presence of diagnostic tests such 
as evoked potentials, the Poser criteria made their appearance (Milo & Miller, 2014). The most 
famous diagnostic criteria are undoubtedly the McDonald criteria, established in 2001, that 
use imaging in order to show lesions in the CNS in space and time (Polman et al., 2011). 
Since these criteria seem to oversimplify the diagnosis of the disease (Milo & Miller, 2014), 
they have been reviewed during the years in order to include a variety of symptoms and make 
use of the state of the art technology . As there is still a lot of debate regarding the criteria that 
should be used for diagnosis, the Lublin and Reingold classification so far seems to be the 
only classification that explains the clinical courses of MS, grouping them in the following 
forms: Relapsing Remitting (RR), Primary Progressive (PP) and Secondary Progressive (SP) 
MS. 
1) RR is characterized by the presence of clearly defined inflammatory recurrences with 
complete recovery or with after effects and deficit residues in the recovery. Periods of 
recurrence are characterized by absence of disease progression (Fig.1.3). This form 




Figure 1.3 Clinical course of Relapsing-Remitting multiple sclerosis.  
There could be present acute attacks with full recovery or residual deficits after recovery (Lublin 




2) The essential element in PP is a gradual and continuous worsening of the clinical 
condition with no distinct relapse but with occasional plateaus (Fig.1.4). This form is 
the rarest course of the disease, around 15% of cases (Polman et al., 2011). 
 
 
Figure 1.4 Clinical course of Primary-Progressive multiple sclerosis.  
There could be progression of disability from onset, without plateaus or remissions; or progression of 















3) SP is characterized by an initial course of the disease such as the RR form followed 
by progression with or without occasional recurrences, minor remissions, and plateaus 
(Fig.1.5). About 80% of RR forms progress to SP in 10-15 years from the onset 
(Polman et al., 2011). 
 
 
Figure 1.5 Clinical course of Secondary-Progressive multiple sclerosis.  
There is an initial RR course, followed by a variable progression or by occasional relapses and 














1.3 AETIOLOGY OF MS 
As previously mentioned, the pathological mechanisms that underlie the aetiology of MS are 
not yet fully understood. The lack of consensus over the causes for MS is depicted by the 
presence in the literature of two antithetic concepts about the MS aetiopathogenesis. The first 
and the most prevalent in the literature states that a faulty immunological attack, driven by 
CD4+ T lymphocytes, leads to myelin destruction and consequently cytodegeneration 
(Holmoy & Hestvik, 2008). This identifies the autoimmune response as the cause for MS and 
was named “outside-in” theory. In contrast, an alternative hypothesis explaining the aetiology 
of MS, was named then “inside-out” theory. This theory suggests that cytodegeneration leads 
to autoimmunity, supporting the idea that the immune system is a secondary player that 
responds to a disrupted brain function (Fig.1.6) (Stys, Zamponi, van Minnen, & Geurts, 2012). 
 
 
Figure 1.1 Scheme of “inside-out/outside-in” models.  
According to the “outside-in” model, MS is an autoimmune disease that causes demyelination and 
tissue injury in CNS. The “inside-out” one instead, states that the early dysregulation occurs in the CNS, 
probably on the oligodendrocyte–myelin complex, and by releasing antigenic proteins, drives a second 










In the “outside-in” theory, the triggering event for the onset of MS occurs when autoreactive 
CD4+ T cells are activated in the periphery, due to a series of genetic and environmental 
factors. These cells enhance the immune response through the recruitment of additional pro-
inflammatory immune cells (including cytotoxic T cells, B cells, granulocytes, monocytes, 
dendritic cells and mast cells), which adhere to the endothelium forming part of the blood-brain 
barrier, and traverse it. After entrance into the CNS, autoreactive CD4+ T cells are reactivated 
by antigen-presenting cells and release pro-inflammatory cytokines (IFN-gamma, Tumour 
Necrosis Factor-alpha) and a variety of chemokines. The release of these factors can amplify 
local inflammation by activating microglia and astrocytes, which can stimulate a myelin attack 
by macrophages with subsequent demyelination and axonal damage. The activation of B cells, 
the production of autoantibodies by the plasma cells, and the involvement of complement 
factors entering the CNS once the inflammation process has been triggered, produce a variety 
of responses that cause further damage to the CNS, related to myelin destruction and axonal 
damage (Fig.1.7) (Holmoy & Hestvik, 2008). 
 
Figure 1.2 Pathogenic mechanisms that intervene in multiple sclerosis.  
(1) According to the cytokine environment, the activated CD4+ T cells mature into subtypes of T helper 
(Th) cells. (2) Activated T cells express the very late activation antigen 4 (VLA-4) and lymphocyte 






The “inside-out” theory rose up in order to explain some phenomena that occur in the disease 
that couldn’t be explained by the “outside-in” model.  
The first discrepancy occurs in the early stage of the disease: as previously described, myelin 
sheath and myelin-specific proteins play a key role in MS and, as pathological and 
immunohistochemical examinations confirm, the disruption occurs in the inner part of axons 
that are still myelinated. In this process the internal lamellae swell, with the loss of myelin-




Figure 1.3 Electron microscopy image of an acute demyelinating lesion of multiple sclerosis. 
(A) The arrow indicates an abnormal oligodendrocyte cell enveloped by an intact myelin sheath. (B) 
The arrow indicates intact inner myelin lamellae (Rodriguez & Scheithauer, 1994). 
 
How could the first event be the immunological response, as affirmed by the “outside-in” 
hypothesis, if the disruption is in the inner part of myelin sheath? Also, through autopsy 
material (post-mortem brain tissue) from patients in early active stages of MS, it has been 
discovered the sole presence of macrophages and microglia in areas of demyelination and 
oligodendrocyte loss, with scarce T and B cell infiltration, meaning that only the innate immune 





Figure 1.4 Autopsy material from patients in early active stages of multiple sclerosis.  
(A) Images of active demyelination with perivascular inflammatory cells, macrophages, myelin debris 
and demyelinated axons. (B) Area of partial demyelination with demyelinated axons and absence of 
inflammatory infiltrates. (C) Oligodendrocytes in area of remyelination. (D) Demyelinated lesions with 
astrocytes and macrophages (Rodriguez & Scheithauer, 1994). 
 
Moreover, in the active cortical MS lesions, a consistent amount of neuritic injury was found 
to have less inflammatory infiltration relative to the rest of the white matter lesions (Peterson, 
Bo, Mork, Chang, & Trapp, 2001), which means that the progression of the degenerative 
process may occur in a different way in the white and grey matter (Fig.1.10). 
 
Figure 1.5 Cortical lesions contain less inflammatory cells than white matter lesions. 
(A) Myelin staining has been performed in order to identify the WM area and the cortical area (divided 
by a red dotted line) and the lesion area (delimited area with yellow dots and arrow). (B) Major 
Histocompatibility Complex class II staining has been performed and shows a higher presence of 
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The second discrepancy is the reduced presence of immune infiltration in the NAWM where 
there are myelin and axonal losses (Fig.1.11), which shouldn’t be the case according to the 
“outside-in” model.(Seewann et al., 2009). 
 
 
Figure 1.6 Normal appearing white matter of a patient showing myelin and axonal loss but 
reduced immune infiltration. 
(A) Bodian silver staining has been performed in order to show nerve endings and nerve fibre tissue on 
a MS brain section. (B) HLA-DR (an MHC class II cell surface receptor) immunostaining of the same 
brain section has been performed in order to highlight the inflammatory process. (1c) NAWM, (2c) 
diffusely abnormal WM (DAWM), (3c) WM lesions. As can be seen through the bodian silver staining, 
there is higher axonal loss in 3c and 2c than 1c. (1d) No activated Antigen presenting cells (APC) found 
in NAWM. (2d) Some activated APCs found in DAWM. (3d) Chronic active lesion with a bulk of activated 
APCs. Considering both the bodian silver staining and the HLA-DR staining, there is a higher presence 
of immune infiltration in the NAWM area where there is axonal loss (Seewann et al., 2009). 
 
The third discrepancy is more clinically related. It has been shown that the immune modulator 
drugs that are administered to RRMS patients are highly effective at reducing either relapses 
or inflammation, but the same compounds are ineffective in PPMS, since, as previously 
described, the onset of the disease is not inflammatory-related (Hawker, 2011). Another 
clinical approach is the autologous hematopoietic stem cells transplantation, this has been 
found to be very effective in reducing the inflammatory activity in the CNS, but it does not stop 
the progression of the demyelination and axonal degeneration (Lu et al., 2010). Why do these 





arguments stating that the degeneration, at a certain stage of the disease, becomes 
independent from the “primary” inflammation (Brotman, Jaffer, Hurbanek, & Morra, 2004). In 
support to the latter, the patients that are treated with the drug Alemtuzumab (a monoclonal 
antibody directed against CD52, which is expressed on lymphocytes) that show a higher 
inflammatory profile at the beginning of the disease, continue to accumulate disability more 
rapidly despite the treatment therapy. However, the immunosuppressing activity of this drug 
can fail to remove pathogenic CNS-resident immune cells, leading to a continuous 
degeneration process (Coles et al., 1999). As such, the observations can also be explained 
with the “inside-out” theory, in which a highly aggressive primary degenerative process causes 
the release of high levels of autoantigens, which cause a secondary inflammatory reaction. In 
this way, even if there is the suppression of the inflammatory reaction, the degeneration will 
still be present. Another clinical observation is the difference in the progression of the MS 
disease, in which the relapsing inflammatory activity is separated from the primary progressive 
course (Scalfari et al., 2010), which means that in these cases the inflammation cannot lead 
to the degeneration. 
The last discrepancy relates to the genetic profile of the disease. The largest genome-wide 
association study on the subject affirms that the major histocompatibility complex II is the key 
player to develop MS in addition to other genes that are involved in T-cell functions. Going 
deeper in this study it was found that 90% of the patients studied were RRMS, which is 
consistent with the strong involvement of immune related genes. The interesting finding is that 
the remaining 10%, composed of PPMS, shows robust associations only with four genes, all 
of them unrelated to the immune system (International Multiple Sclerosis Genetics et al., 
2011). This study confirms the relation between the disease and the immune reactions but, 











1.4 DIAGNOSIS OF MS 
Currently there are no diagnostic laboratory tests to assess MS (Venkateswaran et al., 2010). 
The current procedure involves evaluating patients through neurological examination, blood 
test, MRI (Magnetic Resonance Imaging) scan, lumbar puncture and evoked potential tests 
according to MS diagnostic criteria: the McDonald criteria (McDonald et al., 2001). During the 
neurological examination physical changes, weakness, vision and motor coordination, 
reflexes, balance and speech are tested in order to see whether there are nerve damages 
(NationalMSsociety, 2020). The blood test is performed to exclude other diseases that share 
similar symptoms with MS such as neuromyelitis optica, characterised by the presence of 
aquaporin-4 (AQP4) antibodies. The MRI scan is required in order to see whether lesions are 
present in the brain or in the spinal cord and can also be used to confirm if a lesion has 
occurred at two different places during the time (Broza et al., 2017). The most invasive 
procedure undertaken in order to confirm MS diagnosis is the lumbar puncture. The 
cerebrospinal fluid is taken from spinal canal in order to see the production of antibodies and 
the presence of oligoclonal bands (Diplock, Sullivan, Jaffer, & Opps, 2004). An emerging 
examination is the evoked potential tests, in which the recording of electrical signals, produced 
by the nervous system in response to stimuli (that can be visual or electrical), allows to assess 
the speed of the nerve signalling between neurons. This information is an indirect one of 
myelin status, the membrane responsible for saltatory conduction of impulse, which is 
disrupted in MS disease (Mayoclinic, 2020). The diagnosis of MS is assessed from the 
evidence of lesions in at least two separate areas of the brain or spinal cord, and disseminated 
in time, together with the exclusion of other possible disease that could share MS patterns 
(Omerhoca, Akkas, & Icen, 2018). The assessment of MS types (RRMS, PPMS, SPMS) is 
based on symptoms and the presences of relapses, remissions, clinical degeneration (NHS, 
2020) and, according to the McDonald criteria, on the dissemination of lesions in space and 
time visible through MRI scan. The exact selection of MS type, unfortunately, can be assessed 








1.5 CLASSIFICATION OF MS BIOMARKERS 
According to the Collins dictionary, the definition of biological biomarker is “a substance, 
physiological characteristic, gene, etc that indicates, or may indicate, the presence of disease, 
a physiological abnormality or a psychological condition” (CollinsEnglishDictionary, 2020). The 
entity of a biomarker, which in laboratory routine is commonly identified as a molecule, whether 
this could be a protein, a vesicle, or a compound, is an element of distinction between a healthy 
person and a sick subject. Another even broader definition considers also what affects a 
disease, so not only the presence of the difference, but also the elements that contribute to 
the onset of the disease, such as chemicals or nutrients (Strimbu & Tavel, 2010). 
For MS it is important to have: predictive biomarkers that help to determine the onset of the 
disease before it occurs, or at an early stage, and help with the planning of future treatments; 
diagnostic biomarkers to assess MS diagnosis; disease activity biomarkers that can 
distinguish the different forms of MS disease; treatment-response biomarkers to help 
determine the efficiency of the response to drug therapies (Paul, Comabella, & Gandhi, 2019). 
 
PREDICTIVE BIOMARKERS 
Among the predictive biomarkers there are the genetics biomarkers and the potentially risk 
genes. On the first category (the genetics biomarkers) there is no evidence for a specific gene 
that causes MS, but the presence of antibodies against Epstein–Barr virus nuclear antigens 
(anti-EBNA) in blood seems to correlate with MS disease (Sundstrom et al., 2004). 
Nevertheless, the probability of developing MS with a family history of the disease is about: 
1.5% (1 in 67) if one parent has MS; 2.7% (1 in 37), if a sibling has MS; 20% (1 in 5), if an 
identical twin as MS (Sadovnick, Ebers, Dyment, & Risch, 1996). In the second category (the 
potentially risk genes) there are some genes that make a subject more likely to develop it, 
such as the ones that have a role in the immune system. Some of these genes are related to 
other autoimmune diseases such as Crohn’s disease and rheumatoid arthritis (Zuvich, 
McCauley, Pericak-Vance, & Haines, 2009), while other genes have a connection with the 
lower levels of vitamin D. In 2016, the correlation between body mass index (BMI) and MS 
emerged, identifying that people who are genetically predisposed to have a higher BMI are 











The diagnostic biomarkers, or exploratory biomarkers, are used to assess MS disease. In this 
field, the biomarkers able to determine Clinical isolated syndrome (CIS) are investigated, since 
CIS is a form of MS considered to be the first step into the disease, due to the presence of a 
single lesion (instead of the minimum two lesions required to confirm MS according to the 
McDonald criteria). The majority of the studies are focused on diagnostic biomarkers, as can 
be seen in Fig.1.12, and can be divided in three sub categories: the exploratory biomarkers, 
in which there is still a base research approach, the validated ones, that are confirmed by a 




Figure 1.12 Diagnostic biomarkers currently used (Paul et al., 2019). 
P, Predictive biomarker; D, diagnostic biomarker; DA, disease activity biomarker; AL-R, alemtuzumab-
response biomarker; DC-R, daclizumab-response biomarker; F-R, fingolimod-response biomarker; GA-
R, glatiramer-acetate-response biomarker; IFN-β-R, interferon β response biomarker; MT-R, 
mitoxantrone-response biomarker; NZ-R, natalizumab-response biomarker; MMP, matrix 
metalloprotease;  C3/C4b, complement components C3 and C4b; sCD146, soluble CD146; sCD14, 
soluble CD14; sHLA, soluble human leukocyte antigen; sHLA-G, soluble HLA-G; sNogo-A, soluble 
Nogo-A; anti-Nogo-A; anti-Nogo-A antibodies; anti-MBP, anti-myelin basic protein; anti-MOG, anti-
myelin oligodendrocyte protein; anti-HHV-6, anti-human herpesvirus 6; VEGFA, vascular endothelial 
growth factor A; AMCase, acid mammalian chitinase; Chit, chitinase 1 (chitotriosidase); TNFSF13 (also 
known as APRIL), tumor necrosis factor (ligand) superfamily, member 13; S/GPL, sulphatide and 
glycosphingolipid antibody titers; HMGB1, high mobility group box 1; TOB1, transducer of ERRB2 1; 
NAA, N-acetyl aspartic acid; NSE, neuron-specific enolase; anti-TUb, anti-tubulin antibodies; β-TUb, β-
tubulin isoforms II and III; anti-NEFL, anti-neurofilament light chain antibodies; Tregs, T-regulatory cells; 
KCNK5, potassium channel subfamily K member 5; FGF2, fibroblast growth factor 2; PDGF-AA, 
platelet-derived growth factor-AA; gMS classifier 1, anti-Glc(αl,4) Glc(α) IgM antibodies; myeloid MVs, 
myeloid microvesicles; sAPP, soluble amyloid precursor protein; Aβ peptide, amyloid β peptide; GWAS, 
genome-wide association study; CIITA, class II transactivator; APLA, antiphospholipid antibodies; 
ABCB1, ATP-binding cassette, subfamily B, member 1; ABCG2, ATP-binding cassette, subfamily G, 
member 2; anti-EBNA, antibodies against Epstein–Barr virus nuclear antigens; KFLC, κ-free light chain; 
OB, oligoclonal bands; NCAM1, neural cell adhesion molecule 1; NO metabolites, nitric oxide and its 
metabolites, nitrates, and nitrites; SPP1 (also known as osteopontin), secreted phosphoprotein 1; 
CXCL, CXC ligand 1; GFAP, glial fibrillary acidic protein; BDNF, brain-derived neurotrophic factor; 
KCNJ10 (also known as KIR4.1), potassium inwardly rectifying channel, subfamily J, member 10; MRZ 
reaction, intrathecal humoral immune response against measles, rubella, and varicella zoster virus; 
CHI3L1, chitinase-3-like protein 1; GPC5, glypican-5; BAFF, B-cell activating factor; TNF, tumor 
necrosis factor; NEFH, human neurofi lament heavy chain; NEFL, human neurofilament light chain; 
25(OH) vit D, 25-hydroxyvitamin D; CD56bright NK cells, CD56bright natural killer cells; anti-NZ, anti-
natalizumab antibodies; NAbs, neutralizing antibodies; anti-AQP4, anti-aquaporin 4 antibody; anti-JC 




The lower number of biomarkers clinically used is due to the process required to allow a 
biomarker validated in research studies to become a clinical one. The three characteristics 
that a clinical biomarker should have are 1) reproducibility, meaning that it can be assessed 
worldwide, different laboratories have to give the same result on the same person; 2) high 
sensitivity and specificity, it can be detected with a 100% of confidence and can detect only 










DISEASE ACTIVITY BIOMARKERS 
To this category belong the biomarkers able to distinguish between the different forms of MS 
disease. The presence of oxidative stress and inflammation are a peculiarity of the RRMS, 
while the demyelination and recovery process are characteristics of the PPMS (Lassmann et 
al. 2007). In clinical practice, the distinction between the two forms is made according to the 
symptoms, the progression of the disease and MRI scans. An earlier identification of the forms 
of the disease could allow a better treatment plan, psychological and physical support. 
 
TREATMENT-RESPONSE BIOMARKERS 
The personalised treatment in clinical practice is made possible by pharmacokinetics and 
pharmacodynamics biomarkers. The role of these biomarkers is to predict the failure of the 
treatment, the dose required, the poor or extensive response to the drugs, and the propensity 
in developing side effects. One example is the detection of antibodies against John 
Cunningham virus (JCV) in MS patients that are taking the Natalizumab drug. The presence 
of these antibodies, in fact, can advise about the degeneration in progressive multifocal 
























1.6 TECHNIQUES FOR INVESTIGATION OF BIOMARKERS 
As previously mentioned, the main characteristics in order to validate a biomarker in clinical 
practice are the reproducibility and the specificity. In order to overcome the problems related 
to the traditional methods for testing biomarkers, the automated assays have been introduced, 
reducing the variability of the results (Engel, Jaffer, Adkins, Riddle, & Gibson, 2004). However, 
despite the implementation of these new techniques, the validation of biomarker candidates 
remains elusive, encountering several issues such as the variation among which the 
population studied, the eligibility criteria, the timing of sample collection and the variation 
among the techniques used which include molecular and cellular techniques (Finer, Jaffer, & 
Santerre, 2004). The reasons for one technique being a preferred choice over another remains 
to be clarified for several biomarkers (Teixido, Karachaliou, Gonzalez-Cao, Morales-Espinosa, 
& Rosell, 2015). Among the most used there are PCR (polymerase chain reaction), NGS (next-
generation sequencing), FISH (fluorescent in situ hybridization), IHC (immunohistochemistry), 
Western blot, ELISA (enzyme-linked immunosorbent assay), gel electrophoresis. The 
detection of anaplastic lymphoma kinase (ALK) in a sample is a perfect example to better 
explain the limitation of these techniques: with the PCR it is possible to detect the ALK 
rearrangements, but only with known fusion partners and when high-quality RNA is provided, 
excluding the possibility to extract it from a formalin-fixed paraffin-embedded (FFPE) samples 
(Ying et al., 2013). NGS is able to detect the ALK rearrangements even in FFPE samples, but 
the sensitivity varies among the platforms, some can detect genomic breakpoints located in 
introns, some other can detect the rearrangements only when their breakpoints are adequately 
covered (Soda et al., 2007). Plus, these advanced techniques are not available in all the 
laboratories and the results may require weeks in order to be produced, which in a clinical 
laboratory is a long time for lung cancer patients. FISH is a technique which requires short 
time to process, but the close proximity of ALK gene with other genes may produce false 
positive results and this in turn leads to incremented costs (Travis et al., 2015). IHC instead is 
a cost-efficient methodology, but it requires a uniform standard set of guidelines in order to 
standardize the testing process (Mino-Kenudson, 2017). Efforts in evaluating the strength and 
weakness of these techniques, together with a standardization of protocols for the 
performance and the analysis, will widen the possibilities for the clinical biomarkers to be used 
in clinical practice (Ford et al., 2009). A testing methodology that will explore biomarkers in a 






1.7 XBP1 GENE 
The endoplasmic reticulum (ER) is a structure present in the cell whose prevalent function is 
protein synthesis and transport (Schwarz & Blower, 2016). The malfunction of the ER is strictly 
related to the neurodegenerative disease’s pathways, such as MS, making it worth of attention 
due to its function. The ER is formed by two parts: the rough ER, called this way due to the 
presence of ribosomes attached on the surface; and the smooth ER characterized by the 
absence of the ribosomes (Cubillos-Ruiz et al., 2015). After the mRNA translation into protein, 
a process that occurs in the rough ER, all the sub sequential post-translational modifications 
that activate the proteins take place in the same organelle (Back, Schroder, Lee, Zhang, & 
Kaufman, 2005). Upon accumulation of unfolded proteins, the ER activates a transcriptional 
pathway called unfolded protein response (UPR). This response has two main effects: on one 
side it increases the protein folding and on the other it reduces the protein influx as a safety 
mechanism to reduce ER stress (Bartoszewski et al., 2011). The pathway triggered by UPR 
cascade involves genes of protein transfer, folding, glycation, proteolysis, lipid biosynthesis, 
vesicle transport, and oxidation-reduction metabolism (Shanmuganathan et al., 2019). In 
mammals, this signalling system can be mediated by inositol requiring enzyme one alpha 
(IRE1α), activating transcription factor 6 (ATF6) and pancreatic endoplasmic reticulum kinase 
(PERK) (Walter & Ron, 2011). All of these genes are sensors present in the ER, but the one 
which is evolutionarily conserved is IRE1 (Mori, 2009). In fact, in yeast the activation occurs 
with direct binding of unfolded proteins to the luminal core regions of IRE1 (Gardner and 
Walter, 2011; Kimata et al., 2007), but the same mechanism has not been proved yet in 
mammal cells (Kohno, 2010). IRE1 is a Ser/Thr protein kinase that autophosphorylates after 
unfolded proteins accumulation, and brings to an unconventional splicing in the cytoplasm, 
activating XBP1 gene. XBP1 is a gene that encodes a transcription factor that regulates MHC 
(major histocompatibility complex) class II genes by binding to a promoter element referred to 
as an X box. The splicing is defined as “unconventional”, since the removal of a 26-nt intron 
from XBP1u pre-mRNA, causes a translational frame-shift with a sub sequential replacement 
of the C-terminal into a new one generating XBP1s, which is the functionally active 
transcription factor (Calfon et al., 2002). In the nucleus, XBP1s activates genes encoding ER-
resident chaperone molecules that increase the folding of other proteins, such as transcription 
factors with the bZIP domain, enhances ER associated protein degradation (ERAD) 
components, responsible to degrade the unfolded proteins, and promotes the differentiation 




Figure 1.13 XBP1 pathway (Wheeler et al., 2019).  
On the left side of the figure, the unfolded proteins response pathway is shown, including how it affects 
XBP1 gene regulation, while on the right side an enhanced image of the structure in which the event 
occurs.  
 
ER stress influences the secretory pathways, the lipid metabolism and the immune response. 
These changes are a particular hallmark that can be used to explore the causes of 
neurodegenerative diseases (Yoon et al., 2019). Among these diseases, a recent work has 
highlighted the correlation between gene mutation in autism spectrum disorders (ASD) and 
ER stress. The ER-stressed genes expression has been analysed in post-mortem middle 
frontal gyrus of ASD and found an increase in XBP1 and IRE levels. Apart from that, it was 
found that the higher levels correlate with the diagnostic score for stereotyped ASD behaviour 
(Crider, Ahmed, & Pillai, 2017). Another neuro-disorder involved in ER-stress is schizophrenia: 
among the proteins involved in UPR cascade, in dorsolateral prefrontal cortex, there is an 
increase in XBP1s expression, together with the higher ratio of XBP1s/u transcripts. 
Altogether, these results suggest an increase in IRE1α splicing in schizophrenic patients, 
which means an unbalance in cellular stress response (Kim, Scott, & Meador-Woodruff, 2019). 
Other neurodegenerative diseases correlated with ER-stress are amyotrophic lateral sclerosis 
(ALS) and Alzheimer’s disease (AD), in which the IRE1α-XBP1 pathway is highly activated, 
but, particularly in ALS, XBP1 activation is sustained by an increase of co-chaperone activity 
and ERAD genes (Montibeller & de Belleroche, 2018). Regarding MS, the XBP1 protein 
expression was found to be increased both in lesions and NAWM. Furthermore, there is an 
XBP1s incremental expression in NAWM and normal-appearing grey matter (NAGM) in MS 
astrocytes (Wheeler 2019). Interestingly, in bipolar disorder (BD) the total XBP1 and XBP1u 
levels were decreased in peripheral blood. Thus, the decrease could open the possibility that 
the lower XBP1u expression does not allow the restoration of ER stress level, instead it allows 
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an increase of XBP1s levels. Controversially, the XBP1s/u ratio did not differ between BD and 
controls (Bengesser et al., 2018). However, this does not exclude the possibility to consider 
XBP1 gene as predictive or diagnostic biomarker. 
 
1.8 VOLATILE ORGANIC COMPOUNDS 
Volatile organic compounds (VOCs) are gaseous molecules that are becoming promising in 
the clinical biomarkers field as they can be collected in a fast and non-invasive way. 
They have been described for the first time in 1971 by Linus Pauling, who identified 250 
substances from the breath (Pauling, Robinson, Teranishi, & Cary, 1971). By definition, VOCs 
include all the organic compounds based on carbon molecules, having a vapour pressure of 
0,01 kPa at 293,15 K and a low molecular weight (<1 kDa) (Cicolella, 2008). They are part of 
the exhaled breath and represent the volatile fraction of metabolites.  
They are produced by the human metabolism, and represent the endpoint of gene 
transcription and protein expression. They can originate either from within the body 
(endogenous VOCs) or from external sources such as diet, prescription drugs and 
environmental exposure (exogenous VOCs) (OwlstoneMedical, 2019). 
There are three different types of VOCs that can be detected during a breath test: first, the 
VOCs that arise from metabolic activity in local airways tissue; they are modulated by gene 
activity as they are directly linked with them, therefore any changes in the genomic pathway 
will consequentially lead to a different pattern of molecules (Hurbanek, Jaffer, Morra, Karafa, 
& Brotman, 2004). Second, the VOCs that come from the systemic circulation, as in the lungs 
there is a direct exchange of molecules between the pulmonary system and the circulatory 
system. In 1 minute, the VOCs originated from the body periphery reach the lungs and pass 




Figure 1.14 Exchange from blood to airways (van der Schee et al., 2015).  
In the lungs, the exchange of volatile organic compounds occurs between blood and alveolar air and 
on into exhaled breath. In the alveolus the sources of the volatile organic compounds are blood, tissue 
uptake, local metabolism and bacteria.  
 
Third, the VOCs arising from the microbiome or introduced from the environment, diet or 
prescription drugs metabolites (Boyle & Murphy, 2016). The high specificity rate of VOCs and 
the rapid and pain-free characteristics of the breath biopsy make them a useful tool for the 
investigation of diseases, whose need of biomarkers is urgent. One of the first diseases 
investigated was cancer: the metabolites released in the early stages of the disease, with a 
particular focus on lung cancer, were used as predictive biomarkers, as they are hallmarks 
able to distinguish cancer patients from healthy ones (Krilavicbutesiute et al., 2015). Among 
the inflammatory diseases, the breath biopsy has been used on inflammatory bowel disease 
(IBD), and it was successful not only in distinguishing IBD patients from healthy controls, but 
also in differing between the two forms of this disease (Arasaradnam et al., 2016). This 
powerful tool has also been used in neurodegenerative diseases, such as AD, with the same 
discrimination capacity between AD patients and healthy controls (Mazzatenta, Pokorski, 
Sartucci, Domenici, & Di Giulio, 2015). Regarding the MS field, three breath biopsy studies 
(Ionescu et al., 2011) (Broza et al., 2017) with the usage of gas chromatography mass 
spectrometry (GC-MS), have proven the different variety of VOCs among MS patients and 
healthy controls. In the first study, they found that only hexanal and 5-methylundecane levels 
are higher in MS patients than healthy control. The possible explanation is that these 
compounds are related to lipid peroxidation, an event that contributes to expand the MS 
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cascade. They further validated the results via a blind approach, testing all the participants 
and then assessing them as MS disease patients or as controls thanks to the higher level of 
these two compounds, showing statistically relevant results (Ionescu et al., 2011). In the 
second study instead, the number of compounds that were found higher in MS participants 
amounts to 4: heptadecane, nonanal, decanal and sulphur dioxide. The first three compounds 
participate in the process of lipid peroxidation, while the latter is involved in the oxidative stress 
process. Interestingly, only one compound was found more present in healthy controls respect 
to MS and it’s acetophenone, still involved in lipid peroxidation. Again, the predictive model, 
able to assess the presence of the disease according to the VOCs pattern, generated 
statistically significant results (Broza et al., 2017). The last study is a Master thesis from 
University of Huddersfield conducted by Phoebe Tate and Dr. Patrick McHugh at the Centre 
for Biomarker Research. In this study acetic acid, d-limonene, alpha-pinene and toluene levels 
were found higher in MS patients compared to controls. With the exception of acetic acid, 
which is involved in the fermentation process, the other compounds all have exogenous origin. 
Acetone and methylene chloride levels instead, were reduced in MS participants. Taken 
together all these results reinforce the idea of employing VOCs and breath biopsy as promising 
tools, as the procedure is less invasive than lumbar puncture and quicker since it takes 10 
minutes to perform it, mainly for the clinical related biomarkers, but with an open possibility on 















1.9 PURPOSE OF THE THESIS 
Multiple sclerosis is a complex disease, and its etiopathogenesis is still a matter of debate. 
This has dramatic consequences on the clinical approach to the disease, which presently can 
be effective for a restricted percentage of patients, and on the market, currently ruled by 
immunomodulator drugs (Irshad, Veillard, Roux, & Racoceanu, 2014). For the progressive 
forms of the disease, the most common drugs can help to manage the symptoms, but do not 
eradicate the disease or prevent the relapses. The need of therapeutic targets for the 
progressive disease forms is intertwined to the investments in research to understand not only 
the succession of events that leads to this disease, but also the causes leading to a variability 
among patients (Karussis, 2014). 
This variability is one of the key points in the research of biomarkers for MS, as predictive 
biomarkers can be used to distinguish the various forms of the disease and help with the 
planning of future treatments. Taking into consideration the literature behind, in this thesis the 
XBP1 gene products will be investigated. The first hypothesis to be tested will be the 
expression of both isoforms of XBP1 in both MS patients and healthy controls (CTRL) in post-
mortem human brains in the normal appearing white matter area, in order to see whether there 
will be an altered ratio between the two XBP1 isoforms and if their presence is peculiar to 
either disease form. Also, the expression of these proteins will be evaluated in three areas: 
the frontal cortex (FC), the basal ganglia (BG) and the temporal lobe (TL) in order to explore 
the propensity of accumulation of both the isoforms. To test this hypothesis, 
immunohistochemistry stainings for XBP1u and XBP1s will be performed on 8 MS and 6 
controls post-mortem human brains, and a quantification analysis will evaluate the expression 
of the proteins.  
Another biomarker that will be investigated is a diagnostic biomarker, since the lumbar 
puncture is a painful procedure to assess the MS disease. As the VOCs are becoming a 
promising tool, the second hypothesis will be to evaluate the presence of particular 
compounds only on the MS population, using it as a distinction marker from the healthy 
controls. In order to test this hypothesis, we will perform a breath sampling among MS 
participants and healthy controls with RECIVA breath technology. This technology is non-
invasive and will allow an identification of breath biomarkers relevant for disease occurring 




Figure 1.15 Aims and objectives.  
The core of this thesis are the multiple sclerosis biomarkers. Among these ones, the focus will be on 
XBP1 gene products and volatile organic compounds. The hypothesis will be tested through IHC = 















MATERIALS AND METHODS 
 
2.1 HUMAN BRAIN TISSUE 
Formalin-fixed post-mortem human brain tissues were used for this thesis. This study was 
reviewed and approved by the institutional ethics review committee. The MS cases and the 
controls were selected from the MS Society tissue bank (Imperial College, London), with a 
collection of 8 MS cases with a higher percentage of NAWM and a lower percentage of lesions. 
The patients were between 42 and 88 years (Fig.2.1a) old, with a prevalence of females 
(Fig.2.1b). The controls instead, were a total of 6 cases, ensuring that no patients deceased 
due to neurological disorders were selected (Fig.2.1c). The cases were between 63 and 84 
years old (Fig.2.1a), with equal number of females and males (Fig.2.1b). For both sample 
pools only the FC, BG and TL of WM areas were selected, since they represent three hallmark 
spots for MS disease. Both MS patients and controls brain material was fixed in 4% formalin 
for 1 year, then put in 24% sucrose solution and preserved at -30 °C. Then, slices of 10 μm of 
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Figure 2.1 Immunohistochemistry cases details.  
(A) Age at which the cases died. Mann-Whitney two tailed test p = 0.0413 (B) Representation of the 
sex of the cases, comprehending 3 male controls and 3 female controls; 3 MS males and 5 MS females. 















2.2 IMMUNOISTOCHEMISTRY PLP, XBP1s/u STAINING 
Sections were deparaffinised with heat at 55 °C in an oven for 30 minutes; then slides were 
degreased in two steps xylene 100% for 10 minutes, followed by a scale of ethanol solutions 
(100%,100%, 90%, 70%) for 5 minutes and finally in demiwater for 5 minutes. An antigen 
retrieval step was done in Citrate Buffer pH 6 (Sigma-Aldrich, Nottingham, United Kingdom) 
for 45 minutes; washed with PBS (Phospho-buffered saline- Fisher Scientific, Leicestershire, 
United Kingdom) 3 times for 5 minutes (= washing step). The endogenous peroxidase activity 
was blocked by incubating tissue in 3% H2O2 (Sigma, St. Louis, MO) for 15 minutes; washing 
step. The nonspecific antibody binding was blocked by preincubation with 3% normal GS 
(normal goat serum) for 20 minutes; sections were incubated overnight with primary antibodies 
described in the Table 2 at 4 °C. Biotin-labelled secondary antibodies (Vector Laboratories 
LTD, Peterborough, United Kingdom) were incubated for 2 hours; washing step; avidin-biotin 
complex (Vector kit, Vector Laboratories LTD, Peterborough, United Kingdom) was incubated 
for 1 hour; washing step; visualization step through DAB (diaminobenzidine tetrachloride- 
DAKO, Glostrup, Denmark); Cresyviolet counterstain was performed by 2 minutes incubation. 
Finally, tissue was dehydrated with graded ethanol and xylene prior to mounting with DPX 
(Thermofisher, Chesire, United Kingdom). 
 
Primary Antibody Company Catalog No. Host Dilution 
PLP Abcam AB183493 Rabbit 1:500 
XBP1s Cell Signaling  27901S Mouse 1:250 
XBP1u Abcam AB37151 Rabbit 1:500 
Table 1 Primary antibodies used and respective dilution.  
According to the datasheet of the antibodies provided by the companies, the suggested dilution (1:500), 
a more concentrated (1:250) and a more diluted (1:1000) dilution was used. The correct dilution was 











2.3 IMMUNOFLUORESCENCE XBP1s/u 
For the evaluation of XBP1s and XBP1u protein isoforms in the brain tissue, a single 
fluorescence staining has been performed following the PLP staining protocol up to the 
primary antibody step overnight at 4 °C. AlexaFluor secondary antibodies (Table 3) were 
incubated for two hours, followed by a washing step, and finally the slides were mounted with 
mounting media with DAPI (4'6-Diamidino-2-Phenylindole - Thermofisher, Chesire, United 
Kingdom). The immunofluorescence staining was used only as a qualitative illustration; 
therefore, no quantitative analysis has been performed. 
Secondary Antibody Company Catalog No. Host Dilution 
AlexaFluor 647 Thermo Fisher A21245 Goat anti Mouse 1:1000 
AlexaFluor 488 Thermo Fisher A11001 Goat anti Rabbit 1:1000 
Table 2 Secondary antibodies used and respective dilution.  





The determination of NAWM, lesions, and the antibodies dilution was performed with a 
brightfield microscope (DM5000; Leica Microsystems) using a 10× lens magnification. 
 
CONFOCAL 
The visualisation of XBP1s and XBP1u protein isoforms was done with a confocal microscope 
(Carl Zeiss) through Zen software, using a 40x oil lens magnification. The exposure time was 
1000 ms and three channels were acquired, at 647 nm, 488 nm and UV (ultraviolet) in order 
to visualize respectively, the protein of interest, the background autofluorescence and the 
DAPI staining. 
 
UCL IQ PATH 
The slides were sent to UCL (University College London) at the Neuropathology division and 
were acquired with a standard brightfield microscope. An NDPI viewing software was used in 




2.5 IHC ANALYSIS AND STATISTICS 
WM, GM and lesion areas were analysed through Fiji software. The background was removed 
and the colours deconvoluted. Then “Moments” threshold was applied to images to eliminate 
non-specific staining. Standard scale bars (from pixels to μm) were applied to calculate the 
area of the images. The NAWM areas were selected according to the following criteria: lack 
of overlap between the regions and avoidance of folded tissue portions; no inclusion of GM 
areas (the distinction between WM and GM areas was identified by manual observation on 
brightfield microscopy). The first two criteria were the same also for the lesions and grey matter 
analysis. The measurements were performed through Fiji software and all data (area and % 
of myelin) were collected (Microsoft Office package) and statistically evaluated via GraphPad 
Prism7 software (One-Way ANOVA Dunnett’s multiple comparison test, with a single pooled 
variance for the NAWM comparison and Unpaired parametric t test for NAWM and lesions 
comparison). All the graphs include the mean and standard deviation. The stars present in the 


















2.6 BREATH STUDY POPULATION  
The study was meant to recruit 50 MS participants and 50 healthy controls. Unfortunately, due 
to the Novel Coronavirus pandemic, before the lockdown closure, we were able to collect 13 
MS participants and 15 healthy controls, for a total of 28 participants. Primarily, participants 
who joined the previous breath study conducted at the Huddersfield University and Centre for 
Biomarker Research were contacted through email, also providing them with the results of the 
study and the new information sheet. The other MS participants were recruited from MS clinic 
at Seacroft Hospital in Leeds and at the MS society. The healthy controls were also recruited 
through advertisements at the University of Huddersfield and, for the most part, through family 
members and partners of MS participants. All the participants signed the consent forms before 
undertaking the breath sampling. Only the healthy controls were subjected to exclusion 
criteria, among which: no diagnosis of neurological disorders, blood-borne diseases, cancer 
and diabetes; no history of addiction from abuse substances or drugs; no pregnancies; no 
smoking or vaping. After the compilation of the questionnaire, the MS participants were divided 
both depending on the forms of MS according to the diagnosis (RRMS, PPMS, SPMS) and 
according to the drugs taken. The MS participants were between 28 and 73 years old, with a 
prevalence of females, while the controls were between 30 and 73 years old, with a prevalence 
of males (Fig.2.2). 
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Figure 2.2 Breath biopsy cases details.  
(A) Age of participants. Mann-Whitney two tailed test p = 0.7939 (B) Representation of the sex ratio of 
the participants, comprehending 10 male controls and 4 female controls; 2 MS males and 11 MS 











2.7 BREATH BIOPSY TEST 
Participants were allowed to eat and drink only water, for at least one hour before the test. A 
maximum of two participants were allowed to come to perform the sample collection within 
one hour, up to a total of 15 participants per round due to the availability of the Inert-coated 
metal thermal desorption tubes (C2-CAXX-5149 Markers International, Llantrisant, United 
Kingdom). In fact, the latter were a total of 60 tubes, and for each participant 4 tubes were 
required in order to collect the exhaled breath VOCs from the upper and lower airflows. 
The ReCIVA Breath sampler machine (Owlstone medical ltd, Cambridge, United Kingdom) 
comprises a container where to set the 4 tubes, connected with the one-use ReCIVA face 
mask (01-0880 Owlstone medical ltd, Cambridge, United Kingdom) where the participants 
were asked to breath normally (Fig. 2.3). The participants breathed filtered air in order to avoid 
external VOCs sources, thanks to the presence of the CASPER Portable Air Supply, which is 
composed of an air pump that takes ambient air and forces it through a filter before supplying 
it to the sampling machine. 
 
Figure 2.3 ReCIVA Breath Sampler machine.  
(a) ReCIVA Face mask. (b) Air pump supply. (c) Breath desorption tubes (OwlstoneMedical, 2019). 
 
The ReCIVA is connected with a USB cable to the laptop. The software is able to analyse real-
time the CO2 levels, the pressure, the breathing rate, the collection time (generally around 10 
minutes per participant) and the status of the collection, with the possibility of interruption in 







Figure 2.4 ReCIVA Breath software (OwlstoneMedical, 2019). 
 
Inert-coated metal thermal desorption tubes used after the test were kept at -20°C for a 















2.8 VOCs ANALYSIS AND STATISTICS 
Breath tubes were sent to Warwick University for VOCs analysis and tubes cleaning. An Inert-
coated metal thermal desorption tubes (Markers International, Llantrisant, United Kingdom) 
was inserted in the auto-sampler (Markers International, Llantrisant, United Kingdom). The 
specific bar code present in each tube was inserted manually in the software. The Ultra GC 
run time was of 25 minutes, reducing the overall run time by employing a stand-by split of 
150°C. The temperature was between 40°C and 280°C, increasing of 20°C by minute. A pre-
purging step was applied for 1 minute. The inert-coated metal thermal desorption tube was 
warmed for 10 minutes at 250°C for desorption, while the trap purge was carried out for 1 
minute and cooled to 30°C. The trap purging process was performed for 3 minutes at 300°C. 
The masses between 35-350 (atomic units) were analysed for 25 minutes by TOF-MS (Time-
of-flight Mass spectrometry). The ionisation potential was -70V. To remove the background 
interference the TOF-DS software dynamic background subtraction (DBS) was used, together 
with the integration and deconvolution automatic system. To integrate it was set: Global Height 
Reject: 10000, Global Width Reject: 0.001, Baseline Threshold: 3, and Global Area Reject: 
10000. To identify the compounds the list of the National Institute of Standards and 
Technology (NIST) was compared, with at least a match factor of 450. 
To compare the VOC levels, the one-way ANOVA with Tukey’s post-hoc test has been 

















3.1 XBP1S AND XBP1U IN MS FORMS 
In this thesis XBP1 gene products were evaluated in post-mortem brain tissue of MS patients 
and compared to the non-neurological control ones. The relevance of XBP1 as a biological 
marker for MS disease had been already evaluated by Wheeler and colleagues (Wheeler 
2019), but the evaluation of both XBP1s and XBP1u protein isoforms has never been 
evaluated in three different regions, such as FC, TL and BG. As XBP1 is a gene involved in 
the inflammatory pathway and since a strong component of MS aetiopathogenesis has an 
inflammatory source, the XBP1 gene and its products could be investigated as putative 
biomarkers characterizing MS disease.  
First, for qualitative purpose we wanted to image the XBP1 protein isoforms abundance in the 
tissue with a high magnification and we decided to perform immunofluorescence staining on 
MS tissue in the frontal cortex. As can be seen in Fig. 3.1 the XBP1u protein was detected at 
488 nm and XBP1s at 647 nm with a 40x oil lens magnification. From the figure we can 
appreciate that XBP1u protein surrounds the nuclei (Fig.3.1 a), which it was what we expected, 
while for the XBP1s (Fig.3.1b) we can appreciate the non-perfect circular shape, highlighting 
the stress process inclusions. 
    
Figure 3.1 XBP1 images at confocal microscopy. 
(A) XBP1u detected at 488 nm wavelength. (B) XBP1s detected at 647 nm wavelength. (C) Negative 
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We validated the procedure with a PLP staining both (Fig.3.2a) as a positive control for the 
IHC technique and to discern the NAWM and the lesion areas. We found, as expected, a 
statistically significant difference between the amount of PLP present compared to the XBP1s 
and XBP1u levels (Fig.3.2 e, f). The PLP levels were, in fact, higher compared to the XBP1 
isoforms (PLP vs XBP1s p=0.0241, PLP vs XBP1u p=0.0396) as PLP is the most abundant 
protein present in the myelin sheet, so more present compared to the XBP1 products. XBP1s 
and XBP1u levels were evaluated in MS patients (n=8) and in controls (n=4) for the three 
areas FC, TL, BG through Ordinary One-Way ANOVA Dunnett’s multiple comparison test, 

















































Figure 3.2 IHC technical standardization.  
Representation of IHC stainings acquired at brightfield microscopy. Scale bar 6 mm. (A) PLP staining 
(B) XBP1s staining (C) XBP1u staining (D) Negative control. (E)  All the graphs include the mean and 






in frontal cortex Paired parametric two-tailed t test p=0.0241. (F) PLP and XBP1u levels in MS in frontal 
cortex Paired parametric two-tailed t test p=0.0396. 
 
Surprisingly, the XBP1s levels, the isoform responsible for the folding and the degradation of 
the unfolded proteins, were not differing in all the cases and regions considered (Fig.3.3 a, b, 
c). On the contrary, the XBP1u levels, responsible for the negative feedback, were lower in 
MS patients than in controls in frontal cortex (CTRL vs SPMS p=0.0193, CTRL vs PPMS 
p=0.0286), in basal ganglia (CTRL vs SPMS p=0.009, CTRL vs PPMS p=0.0202) and in 
temporal lobe (CTRL vs SPMS p=0.0005, CTRL vs PPMS p=0.0003) (Fig.3.3 d, e, f). Both 
SPMS (n=4) and PPMS (n=4) have been evaluated as we wanted to ascertain whether a 








































































































































































































Figure 3.3 XBP1 expression in Multiple sclerosis cases and controls.  
Dunnett’s multiple comparison test. (A) XBP1s levels in frontal cortex p=0.2037. (B) XBP1s levels in 
basal ganglia p=0.2147, (C) XBP1s levels in temporal lobe p=0.2099. (D) XBP1u levels in frontal cortex 
CTRL vs SPMS p=0.0193, CTRL vs PPMS p=0.0286. (E) XBP1u levels in basal ganglia CTRL vs SPMS 
p=0.009, CTRL vs PPMS p=0.0202. (F) XBP1u levels in temporal lobe CTRL vs SPMS p=0.0005, CTRL 













3.2 XBP1 S/U RATIO 
According to the results shown above, we found that XBP1u levels were lower in MS patients 
compared to the control ones. As the XBP1u works as negative feedback regulator for the 
XBP1s protein production, we decided to look at the ratio between the two isoforms. The 
XBP1s and XBP1u levels were compared in order to determine if one isoform was more 
present respect to the other, showing an unbalance in the regulatory feedback between 
XBP1u and XBP1s. The isoform ratio test was performed in MS patients (n=8) and in controls 
(n=4) for the three areas FC, TL, BG through Ordinary One-Way ANOVA Tukey’s multiple 
comparison test. Interestingly, the XBP1s levels were significantly higher respect to XBP1u 
levels in all the three areas considered (Fig.3.4 a, c, e) supporting the data previously found 
(Fig.3.3), which support the hypothesis that the XBP1u levels are too low to exercise their 
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Figure 3.4 XBP1 s/u ratio in all Multiple sclerosis forms and controls.  
Tukey’s multiple comparison test (A) XBP1s vs XBP1u levels in frontal cortex CTRL p< 0.0001, SPMS 
p< 0.0001, PPMS p< 0.0001. (B) Percentage ratio distribution of the XBP1 isoforms in frontal cortex in 
the three cases. (C) XBP1s vs XBP1u levels in basal ganglia CTRL p= 0.0005, SPMS p< 0.0001, PPMS 
p< 0.0001. (D) Percentage ratio distribution of the XBP1 isoforms in basal ganglia in the three cases. 
(E) XBP1s vs XBP1u levels in temporal lobe CTRL p= 0.0004, SPMS p= 0.0002, PPMS p< 0.0001. (F) 




















3.3 XBP1 S AND XBP1 U LESIONS 
As the distinctive features of MS are the lesions where the focal demyelination occurs, we 
decided to explore the presence of the XBP1 isoforms in these areas. However, the low 
number of the lesions present (n=5) for FC, BG and (n=2) for TL, do not allow to underline a 
difference in the expression of both XBP1 protein isoforms detected and analysed with 




























































































































































Figure 3.5 XBP1 expression in Multiple sclerosis lesions.  
Unpaired parametric t test (A) XBP1s levels in frontal cortex lesions p= 0.5954. (B) XBP1s levels in 
basal ganglia lesions p= 0.2904, (C) XBP1s levels in temporal lobe lesions p= 0.5627. (D) XBP1u levels 
in frontal cortex lesions p= 0.1299. (E) XBP1u levels in basal ganglia lesions p= 0.2435. (F) XBP1u 













To determine if the presence of an isoform over the other was reflecting what we found for the 
NAWM (Fig.3.4), we decided to apply the same ratio analysis used for the NAWM areas also 
to the lesion areas. A statistically significant difference can be appreciated considering the 
expression of XBP1s in the lesions (here denominated LES S) in TL compared to the 
expression of XBP1u in the lesions (LES U), analysed with Unpaired parametric t test, but due 
to the lower number of lesions present we feel that this analysis should be reinforced widening 
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Figure 3.6 XBP1 s/u ratio in lesions. 
Unpaired parametric t test (A) XBP1s lesion (LES S) and XBP1u lesion (LES U) levels in frontal cortex 
lesions p= 0.0544.(B) Percentage ratio distribution of the XBP1 isoforms in frontal cortex lesions (C) 
XBP1s and XBP1u levels in basal ganglia lesions p= 0.5393. (D) Percentage ratio distribution of the 
XBP1 isoforms in basal ganglia lesions. (E) XBP1s and XBP1u levels in temporal lobe lesions p= 0.004. 






3.4 VOCs IN MS AND HEALTHY CONTROL PARTICIPANTS 
We implemented a breath biomarker assay with the ReCIVA technology. The technique allows 
to test 5 participants per hour, as the collection time amounts to only 10 minutes, during which 
the airflow pressure and the CO2 levels can be monitored in real-time. As can be seen in Fig. 
3.7 at least 44 compounds of interest can be collected in a single test. 
 
 
Figure 3.7 VOCs detectable in a single test. 
In yellow there are highlighted the VOCs present as percentage in a number comprised between 1 and 
10, while in orange the VOCs present over 10. The first two columns on the x axis (identified with the 
code numbers 459266, 458244) are the two tubes that collect the upper airways flow, while the last two 
columns (identified with the code numbers 458250, 458242) are the two tubes that collect the lower 
airways flow. 
 
From the questionnaire given to the participants, we highlighted 10 RRMS and 3 SPMS 
participants. Unfortunately, due to the novel Coronavirus pandemic, the analysis of the MS 










4.1 LEAD BIOMARKERS IN MS FIELD 
CXCL13 
The discovery of B-cell follicles in post-mortem human brains (Magliozzi, et al., 2013) opened 
up the possibility to the “inside-out” theory of MS together with the presence of CXCL13 
chemokine in these ectopic follicle structures. The role of this chemokine, in fact, is to activate 
the CD4+ T cells in order to form the germinal centre (Zotos et al. 2010; Crotty 2012; Victora 
and Nussenzweig 2012) and directs the B cells into secondary lymphoid organs (Cyster 2005; 
Okada and Cyster 2006). The role of CXCL13 as biomarker has become prominent after 
finding the higher expression of CXCL13 in the CSF of MS patients in all the clinical forms 
(CIS, RRMS, SPMS, and PPMS) in comparison to healthy controls (Stilund et al. 2015). The 
levels of CXCL13 correlate also with increased relapse rate, EDSS (Expanded Disability 
Status Scale) score, and lesion burden (Khademi et al. 2011; Matute-Blanch et al. 2017; Paul 
et al., 2019). CXCL13 is a promising disease activity biomarker, as it is able to distinguish 
between the different forms of MS disease. In particular, CXCL13 levels increase in RRMS 
relapses (Khademi et al. 2011) and in CIS cases who later, during time, have been confirmed 
to become MS cases, compared to CIS patients who did not convert (Brettschneider et al. 
2010; Khademi et al. 2011). However, it is not a clinical validated biomarker as the higher 
CXCL13 expression in the CSF has been found also in patients with encephalitic viral 



















Another biomarker found in the CSF of MS patients are the CNS neurofilaments. These 
structures include heavy, medium, light chains and α-internexin filaments, and their expression 
its higher after an axonal insult. In particular, it has been found a higher expression of light-
chain neurofilaments in CSF of MS patients compared to healthy control ones, and their 
expression is correlated with active lesions present in the brain of MS participants, detected 
through MRI scan (Bielekova and McDermott 2015). Light-chain neurofilaments can be 
considered as a prognostic biomarker, as their expression is higher in CIS patients (Disanto 
et al. 2015). Overall, the higher levels of light-chain neurofilaments in the CSF predict the 
conversion from a mild form of MS into a more severe one, as demonstrated for the 
progression during a year from CIS form to clinically defined MS disease (Martínez et al. 2015) 
and the progression to SPMS (Salzer et al. 2010). Light-chain neurofilaments can also be 
potentially considered as a treatment-response biomarker as there is a reduced level in the 
CSF after treatment with fingolimod, natalizumab, and rituximab (Gunnarsson et al. 2011; 
Romme Christensen et al. 2014; Kuhle et al. 2015). Before considering light-chain 
neurofilaments as a clinical biomarker there is the need to validate them in longitudinal cohort 
studies in order to determine if the expression level of light-chain neurofilaments before drug 
treatment is a predictive marker or if the level change is dependent on treatment efficacy. 
 
GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) 
The abnormal expression of proteins in the neuronal or glial cells can be a stronger hallmark 
for a neurodegenerative disease. For example, in the astrocytes an intermediate filament 
protein called GFAP (Jacque et al. 1978) is mainly expressed. The higher levels of GFAP in 
CSF of MS patients have been demonstrated to correlate with astrocyte damage (Rosengren 
et al. 1995; Malmestrom et al. 2003; Norgren et al. 2004) as occurs for the XBP1s incremental 









Other promising biomarkers in the MS field, that can be found in different sample types, are 
the miRNAs, a class of single-strand short non coding RNAs. They modulate gene expression, 
regulate the development and differentiation programs, the proteins synthesis in neuron (Ota 
et al. 1990; Pette et al. 1990) apoptosis, metabolism and angiogenesis (Zhu et al. 2013; Qu 
et al. 2014; Paul et al., 2019). Due to their role, miRNA expression has been correlated with 
several diseases, including cancer, neurodegeneration and autoimmunity (Paul et al., 2019). 
Regarding MS, the expression of the miRNAs has been evaluated in numerous human body 
fluids, among which whole blood, including peripheral blood mononuclear cells (PBMCs) 
(Otaegui et al. 2009; Fenoglio et al. 2011; Martinelli-Boneschi et al. 2012; Keller et al. 2009; 
Cox et al. 2010) and post-mortem brain tissues (Junker et al. 2009). The large variety of the 
miRNAs showed a dysregulation during relapses (Otaegui et al. 2009) and increase in PBMCs 
from RRMS patients compared to healthy controls (Fenoglio et al. 2011). The miR-326 
expression in PBMCs has been found to associate with a worsening in the clinical condition 
both of MS patients and their equivalent in a murine experimental model, the experimental 
autoimmune encephalomyelitis (EAE) mice (Zahednasab and Balood 2014; Paul et al., 2019). 
The detection of miRNAs in the previously mentioned sample types proposes them as 
accessible candidates for the biomarker field but with the need to be further explored. 
 
KIR4.1 ANTIBODIES 
An IHC study (Srivastava et al. 2012) revealed the presence of IgG1 and IgG3 antibodies 
binding glial cells of post-mortem MS brain tissue. The target of these antibodies is the 
potassium channel KIR4.1, with a particular tropism for the end feet of the astrocytes. These 
antibodies have been detected not only in post-mortem human brains, but also in the serum 
of nearly half of MS patients examined (total n=397). As only part of MS patients had this 
autoantibody response (Srivastava et al. 2012) the KIR4.1 is still a controversial biomarker to 
be considered, together with the lack of reproducibility of this study, investigated by several 
other groups (Brickshawana et al. 2014; Nerrant et al. 2014; Brill et al. 2015; Chastre et al. 
2016; Pröbstel et al. 2016). However, this might be explained due to the fact that Srivastava 
et al focused mostly on the lower-glycosylated isoform of KIR4.1 expressed in 
oligodendrocytes (Marnetto, Valentino, Caldano, & Bertolotto, 2017). Taken together, all these 
results do not exclude the possibility to considerate the KIR4.1 channel as an emerging 





As previously described, there is no evidence for a specific gene causing MS, but there are 
potentially risk genes that make person more exposed to develop it, namely the ones that 
have a direct or indirect role in the immune system such as XBP1 or TOB-1. The TOB-1 gene 
inhibits T-cell proliferation and its downregulation is directly correlated with an enhancement 
of the immune response, facilitating the conversion from CIS form to clinically defined MS 
disease (Corvol et al. 2008; Paul et al., 2019). 
 
GUT MICROBIOME 
The gut microbiome is a recent hot topic that has been discovered playing a role in several 
diseases including cancer, type 1 diabetes, IBD, rheumatoid arthritis and MS (Scher et al. 
2013; Kostic et al. 2014; Alkanani et al. 2015). For what concerns the MS field, the alteration 
of the gut microbiome of EAE mice leads to the CNS autoimmunity (Lee et al. 2011) and the 
ingestion of commensal microbiota protects against the disease exacerbation (Ochoa- 
Repáraz et al. 2010). In a NGS study (Jangi et al. 2016), the gut microbiome of MS subjects 
was compared to the healthy controls one, an alteration of bacteria population and has been 
found in the MS participants, correlated with an increase in the expression of genes active in 
IFN (Interferon) signalling, dendritic-cell maturation and nuclear factor (NF)-κB signalling 
pathways in circulating T cells and monocytes (Paul et al., 2019; Brown et al., 2020). In the 
same study, patients treated with IFN-β and glatiramer acetate show a higher expression of 
two types of bacteria compared with all the other MS participants. MS patients of the second 
cohort tested with a breath biopsy procedure showed in their breath a higher presence of 
methane compound compared to non-neurological subjects, that can correlate with an 
increase of the Methanobrevibacter genus in the gut of MS patients of the first cohort (Jangi 
et al. 2016). There is the need of further studies in order to understand if the alterations in the 









4.2 XBP1 EXPRESSION IN MS PATIENTS 
XBP1 is a gene involved in the immune system function and ER stress. Its products are 
balanced in order to prevent the triggering of the unfolded protein response and to maintain 
the cytoplasm homeostasis (Issenman & Jaffer, 2004). Our findings, even if at the proteomic 
level, show a decrease of XBP1u protein in MS cases and the unbalance in the XBP1s/u ratio. 
As previously described, these results are in line with other neurodegenerative diseases 
pattern, in which XBP1 and XBP1u levels were decreased in blood of bipolar disorder 
(Bengesser et al., 2018), ALS and AD patients (Montibeller & de Belleroche, 2018). Contrarily 
to other neuro-disorders, while the XBP1s/u ratio in the bipolar disorder was not significantly 
altered (Bengesser et al., 2018), our results suggest a decrease in the XBP1u levels. 
Regarding the expression of both isoforms of XBP1 protein in the lesion area, the n size needs 
to be increased to reinforce a statistically significant difference between the two. Nevertheless, 
they were both upregulated in the FC area, mirroring the evidences found by Wheeler et al 
(Wheeler 2019). Overall, the main finding of this thesis is the reduction of XBP1u levels, which 
is considered a negative feedback regulator for XBP1s production, responsible for the UPR. 
Contrarily to our study, Kim et al found an increased expression of XBP1s but looking at mRNA 
levels in Schizophrenia patients (Kim et al., 2019).  The differences with other studies highlight 
the need to investigate deeper the role of these proteins in MS disease, expanding the 
research focus on the grey matter areas and increasing the n size.   
 
4.3 VOCs AND THEIR POTENTIAL 
The selectivity and specificity rate of VOCs and the ease of use in performing the breath biopsy 
allow to employ this technique as a powerful tool to identify diagnostic biomarkers. As 
previously mentioned regarding the MS field, the technique used to assess MS is the lumbar 
puncture, a painful technique which requires highly qualified medical personnel to perform it. 
The potentiality of VOCs has already been demonstrated in lung cancer, since they were 
employed to discern cancer patients from healthy ones (Krilaviciute et al., 2015), in IBD 
(Arasaradnam et al., 2016) and in AD (Mazzatenta et al., 2015). The emerging role in the MS 
field is promising and needs to be further explored, the preliminary results (Ionescu et al., 
2011) (Broza et al., 2017) and Dr McHugh’s studies reinforce the possibility to further employ 
VOCs and breath biopsy, as it is reliable, quick and easy to perform. Unfortunately, due to the 
novel Coronavirus pandemic, the analysis of the tests performed in this thesis could not have 
been done, but the positive answers from the participants experiencing the test suggest that 
the breath biopsy is a non-invasive procedure that should be further explored in order to make 
it a clinical routine practice. 
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4.4 IHC AS BIOMARKER DETECTION TECHNIQUE 
IHC is a technique based on the antibody-antigen recognition principle, that allows to visualize 
targets, such as proteins, in a colorimetric or fluorescent way (Brandtzaeg, 1998). It is a multi-
step procedure involving fixation and permeabilization steps, implemented by Coons et al, in 
1941 (Coons, Creech, & Jones, 1941). Routinely, IHC is used to detect specific proteins, 
phosphoproteins and/or cell types, with the final outcome of identifying the physiological state 
of the tissue/cell, evaluating the disease characteristics and compare them with healthy ones, 
and contribute to the characterization of the aetiopathogenesis process behind the disease of 
interest (Gurcan et al., 2009). The IHC provides information not only on the condition of the 
tissue, but also on the position of the target analysed, its expression and possible spatial 
connection between several targets (Jones, 1941). This analysis allows to implement the 
biomarker involvement in the disease screening as a prognostic, diagnostic and treatment-
response tool, and it has already been employed in cancer research (Irshad et al., 2014). In 
fact, IHC is used to identify the subtype of tumours and to discern between benign and 
malignant cell types (Leong & Wright, 1987). According to the American Society of Clinical 
Oncology (ASCO) and College of American Pathologists (CAP), in order to test the presence 
of human epidermal growth factor receptor-2 (HER2) in breast cancer, a standard IHC routine 
with score system is recommended (Wolff et al., 2014). In the biomarker field, IHC has been 
proven to have both a prognostic and a treatment-therapy value for epidermal growth factor 
receptor (EGFR), programmed death ligand-1 (PD-L1), anti-FGFR (fibroblast growth factor 
receptor) and anti-cMET (hepatocyte growth factor receptor) (Redman, Crowley, Herbst, 
Hirsch, & Gandara, 2012). Ultimately, IHC confirms RNA and protein signals detected with 
other molecular techniques, providing assurance for otherwise questionable targets (Chae et 
al., 2017). The usage of IHC in biomarker research is due to the availability of the technique, 
the meaningful results, the timing required (usually 2 days) and the cost efficiency compared 
to molecular platforms (Mino-Kenudson, 2017). In this thesis, the role of IHC in the discovery 
of XBP1 impairment in MS disease was fundamental and allowed to detect not only the 
position of the proteins and their expression, but also to visualize them in the brain. Therefore, 
even if lot of effort needs to be done in order to standardize the quantitative analysis, the IHC 







4.5 IHC LIMITATIONS 
Although IHC has numerous advantages, the use of this technique needs to be performed 
being aware of pros and cons. One of the main limitations is to translate the qualitative staining 
images into quantitative analysis. Therefore, lots of efforts have been done in order to create 
an automation system, not only for the time required in order to manually quantify the presence 
of biomarkers, but also to create a standard methodology that will improve accuracy and 
sensitivity (Sheikhzadeh, Ward, van Niekerk, & Guillaud, 2018). The skills of the personnel 
required to perform and interpret IHC stainings, is another variability in the reproducibility of 
the results (Jaffer & Bleiweiss, 2004). As the procedure is based on the antibody-antigen 
recognition, is important to notice the possibility of false positives, as the antibody may 
recognize multiple epitopes, lacking on specificity (Yaziji & Barry, 2006). Finally, adequate 
tissue handling and selection of tissue samples are the key points to successfully perform an 
IHC, not only for predictive biomarkers, but also for protein expression in general (Mino-
Kenudson, 2017). 
 
4.6 FUTURE EXPERIMENTS 
The increment of the n size for the XBP1 study is necessary in order to validate the difference 
between the XBP1 isoforms and will enhance knowledge of the presence of these proteins 
not only in other brain areas such as the NAGM and the lesion areas, but also in other CNS 
structures such as astrocytes, oligodendrocytes and so on. With regards to the Breath biopsy 
project, the methodology implementation will be a solid basis to carry on the study first with a 
small cohort, then to England population, hoping to bring it forward to the European one. 
 
4.7 CONCLUSIONS 
This thesis has added the foundation to better explore the role of XBP1 proteins in the MS 
disease, highlighting the difference in expression of the two isoforms and the dysregulation of 
protein levels between MS patients and healthy controls. Regarding the breath biopsy study, 
the usage of VOCs as diagnostic biomarkers has already been demonstrated and needs 
further insights in the MS area. However, the usage of breath biopsy in clinical practice is a 
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